OPRK1; TSHR; NPSR1; CXCR1; NMUR2; | |
DRD4; ADORA3; ADORA2A; ADORA1; ADRA2C; ADRA2A; CNR1; CNR2; | |
ALPL; TDP1; PLA2G1B; CES1; RECQL; P4HB; TERT; ADK; PIK3R1; GLO1; HPGD; MPO; AKR1B1; HSD17B10; ALOX15; ALDH1A1; HSD17B2; ALOX12; NOX4; USP2; BRCA1; PYGL; POLB; CES2; | |
PTPN11; PTPN6; | |
ACHE; GAA; | |
HDAC3; | |
TRPV1; TRPA1; | |
AKT1; MET; CAMK2B; CSNK2A1; DAPK1; NEK2; FLT3; SRC; IGF1R; PTK2; AURKB; GSK3B; KDR; CDK1; MAPK1; PIM1; NUAK1; ALK; AXL; NEK6; ATM; PKN1; PTK2B; | |
CA5B; CA3; CA7; CA5A; CA1; CA9; CA14; CA4; CA6; CA2; CA12; | |
PPARA; PPARD; | |
KDM4E; | |
MAOA; ALOX5; XDH; | |
CASP7; CASP1; | |
MMP13; MMP3; MMP2; MMP9; | |
BACE1; | |
TLR2; | |
STAT6; HIF1A; NFKB1; TP53; | |
KMT2A; | |
FUT7; | |
SLC28A2; SLC28A1; SLC28A3; | |
ABCC1; ABCG2; | |
LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; HTT; HBB; RAB9A; NPC1; APAF1; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | CES1 | Acyl coenzyme A:cholesterol acyltransferase | P23141 | CHEMBL2265 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Histone deacetylase | HDAC3 | Histone deacetylase 3 | O15379 | CHEMBL1829 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | OPRK1 | Kappa opioid receptor | P41145 | CHEMBL237 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | ATM | Serine-protein kinase ATM | Q13315 | CHEMBL3797 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | PTK2B | Protein tyrosine kinase 2 beta | Q14289 | CHEMBL5469 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
Protein Phosphatase | PTPN6 | Protein-tyrosine phosphatase 1C | P29350 | CHEMBL3166 |
SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APAF1 | Apoptotic protease-activating factor 1 | O14727 | CHEMBL1795093 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.641E-13 | 1.706E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.578E-13 | 1.962E-10 | ADORA1, ADORA2A, ADRA2A, ATM, AURKB, CA2, CA7, CNR1, HIF1A, HTT, KDR, MAPK1, NEK2, NPC1, NPSR1, OPRK1, PLA2G1B, PTK2B, PTPN6, SRC, TRPA1, TRPV1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.344E-12 | 3.801E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2C8, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.546E-11 | 3.783E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.729E-11 | 1.409E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.050E-11 | 1.462E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.284E-09 | 1.928E-07 | ADORA1, ADORA2A, CA2, CA7, HTT, KDR, NPSR1, PLA2G1B, PTK2B, PTPN6, SRC, TRPA1, TRPV1 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.840E-09 | 2.653E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.524E-09 | 4.857E-07 | ADORA2A, ATM, AURKB, CA2, CA7, CNR1, HIF1A, HTT, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B |
MF | GO:0005488; binding | GO:0005524; ATP binding | 5.993E-09 | 8.006E-07 | ABCC1, ABCG2, ADK, AKT1, ALK, APAF1, ATM, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PTK2B, PYGL, RECQL, SRC, TP53, TRPV1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.014E-09 | 1.155E-06 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.837E-08 | 5.163E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 4.903E-08 | 5.204E-06 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, PTPN11, PTPN6, SRC |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 6.340E-08 | 6.482E-06 | CYP1A1, CYP2A13, CYP2A6, CYP2D6 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 6.858E-08 | 6.946E-06 | CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.624E-08 | 8.346E-06 | BRCA1, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, KMT2A, L3MBTL1, MMP13, MMP2, MMP3, MMP9, PPARA, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.502E-07 | 1.329E-05 | AKT1, ATM, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 4.511E-07 | 3.707E-05 | AKT1, HIF1A, LMNA, P4HB, PPARD, SRC, TERT, TP53 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 6.098E-07 | 4.820E-05 | AKT1, ALPL, BRCA1, CASP7, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, NPC1, SRC, TRPV1 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 8.505E-07 | 6.408E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 1.041E-06 | 7.765E-05 | CA3, CDK1, CNR1, HPGD, OPRK1, POLB, PTK2B, TP53 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.531E-06 | 1.097E-04 | ABCC1, ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, AXL, BACE1, CNR1, CNR2, DRD4, FLT3, IGF1R, KDR, MET, NPC1, NPSR1, OPRK1, SLC28A1, SLC28A2, SLC28A3, TLR2, TRPA1, TRPV1, TSHR |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.252E-06 | 1.513E-04 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, AXL, CNR1, CNR2, CXCR1, DRD4, FLT3, HPGD, IGF1R, KDR, MET, NMUR2, NPC1, NPSR1, OPRK1, PTK2B, PTPN6, TRPV1, TSHR |
BP | GO:0050896; response to stimulus | GO:0043279; response to alkaloid | 2.427E-06 | 1.606E-04 | ADORA2A, CASP7, CNR1, OPRK1, PTK2B, TP53, TRPV1 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.815E-06 | 1.803E-04 | CYP1A1, CYP2C8, CYP3A4 |
MF | Unclassified; | GO:0004872; receptor activity | 2.951E-06 | 1.885E-04 | ADORA1, ADORA2A, ADORA3, ADRA2A, ADRA2C, ALK, AXL, CNR1, CNR2, CXCR1, DRD4, FLT3, HPGD, IGF1R, KDR, MET, NMUR2, NPC1, NPSR1, OPRK1, PPARA, PPARD, PTK2B, PTPN6, TLR2, TRPV1, TSHR |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.148E-06 | 1.998E-04 | ALOX12, ALOX15, ALOX5, HPGD |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 4.109E-06 | 2.499E-04 | ADORA1, ADORA2A, ADORA3, ATM, CYP1B1, FABP3, KMT2A, LMNA, NOX4, PKN1, PPARD, PTK2B, PTPN6, TERT, TLR2, TP53, XDH |
BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 4.120E-06 | 2.499E-04 | ADORA2A, AKT1, CASP1, KDR, MAPT, SRC |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 5.238E-06 | 3.083E-04 | AKT1, HIF1A, PTK2B, TERT |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 5.562E-06 | 3.256E-04 | AKT1, BRCA1, DAPK1, HTT, LMNA, SRC, TERT |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 5.603E-06 | 3.271E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.730E-06 | 3.877E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B, TRPV1 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 8.222E-06 | 4.650E-04 | AXL, KDR, PIK3R1, PTK2, PTK2B, SRC |
CC | GO:0044464; cell part | GO:0005829; cytosol | 8.545E-06 | 4.783E-04 | ADK, AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APAF1, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDK1, CES1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HBB, HDAC3, HIF1A, HPGD, HTT, KMT2A, LMNA, MAPK1, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PTK2B, PTPN11, PTPN6, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, TP53, TRPV1, XDH |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 9.757E-06 | 5.298E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 1.009E-05 | 5.465E-04 | CA2, HDAC3, PTK2B, SRC |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.095E-05 | 5.859E-04 | ADRA2A, AKT1, CNR1, HIF1A, NOX4, PIK3R1, PTPN11, PYGL |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.152E-05 | 6.132E-04 | ADORA1, ADORA2A, CNR2, CYP19A1, NFKB1, PPARA, PPARD |
BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 1.219E-05 | 6.412E-04 | AXL, FLT3, HIF1A, KMT2A, PKN1, POLB, PTPN11 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.227E-05 | 6.422E-04 | HPGD, MMP2, MMP9, TERT |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.272E-05 | 6.610E-04 | ADRA2A, AKT1, ATM, CDK1, DAPK1, GSK3B, HIF1A, HTT, KDR, PPARA, PTK2, PTK2B |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.450E-05 | 7.446E-04 | IGF1R, KDR, PTK2, PTK2B, SRC |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.554E-05 | 7.836E-04 | ADRA2A, ADRA2C, DRD4 |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 1.928E-05 | 9.477E-04 | ALOX5, APAF1, CXCR1, FABP5, GAA, HBB, MAPK1, MMP9, MPO, NFKB1, PTPN6, PYGL, TLR2 |
MF | Unclassified; | GO:0032403; protein complex binding | 2.002E-05 | 9.722E-04 | ACHE, ADORA1, ADRA2A, ATM, FLT3, IGF1R, KDR, MMP13, MMP9, P4HB, PIK3R1, PPARA, PTK2B, PTPN11, SRC, TLR2, TSHR |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.089E-05 | 1.006E-03 | FABP2, FABP3, FABP4, FABP5 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.276E-05 | 1.092E-03 | ADK, AKR1B1, AKT1, ALOX5, ATM, AURKB, BRCA1, CAMK2B, CASP7, CDK1, CSNK2A1, FABP5, GSK3B, HDAC3, HIF1A, HPGD, HTT, KMT2A, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NUAK1, PIM1, PKN1, POLB, PPARA, PPARD, PTPN11, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TP53, USP2 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.287E-05 | 1.095E-03 | AKT1, ATM, AURKB, BRCA1, CSNK2A1, L3MBTL1, NUAK1, TP53 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 2.319E-05 | 1.107E-03 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.367E-05 | 1.128E-03 | ABCG2, CA12, CA2, CA7, DRD4, HIF1A, HTT, MAPK1, NMUR2, NPSR1, PLA2G1B, PTK2B, TP53, TRPA1, TRPV1 |
BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 2.445E-05 | 1.150E-03 | AKT1, ATM, AURKB, BRCA1, HIF1A, KMT2A, NOX4, OPRK1, PIK3R1, POLB, TP53, USP2 |
BP | GO:0050896; response to stimulus | GO:0060359; response to ammonium ion | 2.616E-05 | 1.217E-03 | CASP7, CNR1, DRD4, MAPK1, OPRK1, PTK2B |
BP | GO:0050896; response to stimulus | GO:2001025; positive regulation of response to drug | 2.869E-05 | 1.318E-03 | ADORA2A, DRD4, KMT2A, OPRK1 |
MF | GO:0005488; binding | GO:0019901; protein kinase binding | 2.992E-05 | 1.366E-03 | ADRA2A, AKT1, GSK3B, HIF1A, MAPK1, NEK6, PIK3R1, PKN1, PTK2, PTK2B, PTPN11, PTPN6, SRC, TP53 |
BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 3.007E-05 | 1.370E-03 | ADORA1, ADORA2A, ADRA2A, AKT1, DRD4, HTT, NPSR1, OPRK1, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 3.330E-05 | 1.498E-03 | ATM, AURKB, CDK1, PKN1 |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.398E-05 | 1.522E-03 | ABCC1, ADORA1, ADRA2A, CA2, CA4, CA9, HPGD, TSHR |
BP | GO:0008152; metabolic process | GO:0010506; regulation of autophagy | 3.858E-05 | 1.704E-03 | AKT1, ATM, CASP1, DAPK1, HIF1A, HTT, KDR, MAPT, MET, NPC1 |
BP | GO:0051179; localization | GO:0043271; negative regulation of ion transport | 4.310E-05 | 1.867E-03 | ADORA1, ADRA2A, AKT1, CNR1, DRD4, MMP9, PTK2B |
BP | GO:0009987; cellular process | GO:0033277; abortive mitotic cell cycle | 4.357E-05 | 1.867E-03 | PTPN11, PTPN6 |
BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 4.357E-05 | 1.867E-03 | SLC28A2, SLC28A3 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.357E-05 | 1.867E-03 | ALOX12, ALOX15 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 4.357E-05 | 1.867E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.357E-05 | 1.867E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 4.357E-05 | 1.867E-03 | CYP2A13, CYP2A6 |
MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 4.357E-05 | 1.867E-03 | SLC28A2, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 4.411E-05 | 1.872E-03 | FLT3, PTK2, PTK2B, SRC |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 4.511E-05 | 1.896E-03 | IGF1R, PIK3R1, PTPN11 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 4.511E-05 | 1.896E-03 | GSK3B, HTT, MAPT |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 4.715E-05 | 1.970E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN11 |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 4.814E-05 | 2.002E-03 | ADORA1, ADORA2A, DRD4, PPARA, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 5.039E-05 | 2.078E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 5.221E-05 | 2.137E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0009987; cellular process | GO:0045595; regulation of cell differentiation | 5.243E-05 | 2.142E-03 | ADRA2C, AKT1, AXL, CA2, CAMK2B, CDK1, CNR1, GSK3B, HDAC3, HIF1A, KDR, KMT2A, L3MBTL1, MAPK1, MAPT, NFKB1, PIK3R1, PPARA, PPARD, PTK2, PTK2B, PTPN6, TERT, TLR2, TRPV1, XDH |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.729E-05 | 2.323E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0090399; replicative senescence | 5.986E-05 | 2.400E-03 | ATM, TERT, TP53 |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 6.365E-05 | 2.538E-03 | GSK3B, KDR, PIK3R1, PTK2, PTK2B, SRC |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.943E-05 | 2.749E-03 | AXL, MET, NOX4, PIK3R1, PTK2, PTPN11, SRC |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 7.314E-05 | 2.844E-03 | ADRA2A, ADRA2C, AKT1, SRC |
BP | GO:0032501; multicellular organismal process | GO:0051930; regulation of sensory perception of pain | 7.314E-05 | 2.844E-03 | ADORA1, ADRA2C, NMUR2, OPRK1 |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 7.314E-05 | 2.844E-03 | ATM, AURKB, MAPK1, NEK2 |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 7.540E-05 | 2.916E-03 | ALOX12, BRCA1, CYP1B1, HIF1A, KDR, PTK2B, TERT |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 7.639E-05 | 2.949E-03 | FLT3, KDR, PPARD, PTK2, PTPN6 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 7.744E-05 | 2.979E-03 | ADORA2A, CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 8.816E-05 | 3.325E-03 | AKT1, HIF1A, NFKB1, PPARA, SRC |
BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 8.816E-05 | 3.325E-03 | ATM, BRCA1, PIK3R1, POLB, TP53 |
BP | GO:0009987; cellular process | GO:0032872; regulation of stress-activated MAPK cascade | 9.424E-05 | 3.526E-03 | AKT1, HDAC3, IGF1R, MAPK1, OPRK1, PKN1, PTK2B, XDH |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.013E-04 | 3.757E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 1.026E-04 | 3.792E-03 | NEK6, PPARA, TERT, TP53 |
BP | GO:0009987; cellular process | GO:2000045; regulation of G1/S transition of mitotic cell cycle | 1.036E-04 | 3.824E-03 | AKT1, ATM, CDK1, CYP1A1, PTPN6, TERT, TP53 |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.140E-04 | 4.174E-03 | AKT1, CASP1, CASP7, PTK2 |
CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 1.159E-04 | 4.233E-03 | ALOX15, CNR2, PTK2, PTK2B, SRC |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.173E-04 | 4.280E-03 | ADORA1, ADORA2A, ADRA2A, ADRA2C, AXL, HIF1A, NFKB1, P4HB, PIK3R1, PPARD, TLR2, TP53 |
BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 1.214E-04 | 4.420E-03 | AKT1, AXL, CA2, CNR1, HIF1A, MAPK1, MMP2, NFKB1, PIK3R1, PLA2G1B, PTK2, PTK2B, PTPN11, PTPN6, SRC, STAT6, TLR2, TP53 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.237E-04 | 4.489E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.239E-04 | 4.489E-03 | CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HSD17B2, NOX4, RAB9A, SLC28A3 |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.291E-04 | 4.563E-03 | ALOX15, GSK3B, MAPT, MET, MMP3, PTK2B, SRC, TP53 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.301E-04 | 4.563E-03 | SLC28A1, SLC28A3 |
BP | GO:0032501; multicellular organismal process | GO:0050968; detection of chemical stimulus involved in sensory perception of pain | 1.301E-04 | 4.563E-03 | TRPA1, TRPV1 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.301E-04 | 4.563E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.301E-04 | 4.563E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.301E-04 | 4.563E-03 | SLC28A1, SLC28A3 |
BP | GO:0032501; multicellular organismal process | GO:0050955; thermoception | 1.301E-04 | 4.563E-03 | TRPA1, TRPV1 |
MF | GO:0005215; transporter activity | GO:0097603; temperature-gated ion channel activity | 1.301E-04 | 4.563E-03 | TRPA1, TRPV1 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.301E-04 | 4.563E-03 | CYP1A1, CYP3A4 |
MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 1.301E-04 | 4.563E-03 | CNR1, CNR2 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.301E-04 | 4.563E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.301E-04 | 4.563E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.301E-04 | 4.563E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047374; methylumbelliferyl-acetate deacetylase activity | 1.301E-04 | 4.563E-03 | CES1, CES2 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.301E-04 | 4.563E-03 | ADORA1, ADORA2A |
BP | GO:0002376; immune system process | GO:0061515; myeloid cell development | 1.398E-04 | 4.846E-03 | PTPN11, PTPN6, SRC, TLR2 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.483E-04 | 5.104E-03 | BACE1, CNR1, KDR, MAPK1, NPC1, PTK2B, SRC, STAT6, TLR2 |
CC | GO:0044464; cell part | GO:0030673; axolemma | 1.494E-04 | 5.124E-03 | ADORA1, ADORA2A, MAPT |
MF | GO:0005488; binding | GO:0051219; phosphoprotein binding | 1.498E-04 | 5.128E-03 | MAPK1, PIK3R1, PTPN6, SRC, TRPV1 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.541E-04 | 5.251E-03 | AKT1, HBB, PTK2B, TRPV1 |
BP | GO:0009987; cellular process | GO:0071356; cellular response to tumor necrosis factor | 1.553E-04 | 5.275E-03 | AKT1, BRCA1, FABP4, MAPK1, NFKB1, TRPV1 |
BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 1.558E-04 | 5.284E-03 | ADORA1, ADRA2A, ADRA2C, FLT3, PTK2B, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 1.653E-04 | 5.556E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, BRCA1, CES1, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B |
BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 1.694E-04 | 5.639E-03 | ATM, CAMK2B, GSK3B, MAPK1, MAPT |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 1.739E-04 | 5.774E-03 | ACHE, ADORA2A, CASP1, HIF1A, PLA2G1B, PPARD, SRC, TLR2 |
BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.775E-04 | 5.840E-03 | ADORA1, ADORA2A, ADRA2A, ADRA2C, AKT1, PPARD |
BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 1.806E-04 | 5.895E-03 | MAPT, TLR2, TRPV1 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.806E-04 | 5.895E-03 | AURKB, MAPK1, NEK2 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.806E-04 | 5.895E-03 | AURKB, CDK1, PKN1 |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.859E-04 | 6.051E-03 | AKT1, PIK3R1, PTPN11, TERT |
BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 1.923E-04 | 6.249E-03 | ADORA2A, ALK, DRD4, GAA, NPC1, OPRK1, USP2 |
BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 2.204E-04 | 7.068E-03 | AURKB, CDK1, HDAC3, HTT, LMNA, MAPT, NEK2, NEK6, PTK2 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 2.221E-04 | 7.071E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0010595; positive regulation of endothelial cell migration | 2.536E-04 | 7.960E-03 | AKT1, HIF1A, KDR, MET, PTK2B |
BP | GO:0032501; multicellular organismal process | GO:0035162; embryonic hemopoiesis | 2.548E-04 | 7.985E-03 | HIF1A, KDR, KMT2A |
BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 2.585E-04 | 8.027E-03 | AKT1, ALOX12, ALOX15, GSK3B, KDR, PIK3R1, PTK2B, PTPN11, PTPN6, SRC |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 2.592E-04 | 8.027E-03 | NMUR2, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.592E-04 | 8.027E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.592E-04 | 8.027E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 2.592E-04 | 8.027E-03 | CNR1, CNR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.592E-04 | 8.027E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0032795; heterotrimeric G-protein binding | 2.592E-04 | 8.027E-03 | ADORA1, ADRA2A |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.679E-04 | 8.226E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0051493; regulation of cytoskeleton organization | 2.713E-04 | 8.321E-03 | ALOX15, BRCA1, GSK3B, MAPK1, MAPT, MET, NEK2, NOX4, PIK3R1, PTK2, PTK2B |
BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 3.024E-04 | 9.151E-03 | AKT1, ALOX12, CDK1, CSNK2A1, MAPT, PIM1, PPARD, PTK2B |
CC | GO:0044464; cell part | GO:0030424; axon | 3.187E-04 | 9.558E-03 | ADRA2C, BACE1, CA2, CNR1, HTT, MAPK1, MAPT, PTK2B |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.311E-22 | 4.309E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.461E-17 | 7.064E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.012E-16 | 9.180E-14 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, NOX4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.336E-15 | 3.631E-12 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, MPO, NOX4, SRC |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.639E-15 | 4.881E-12 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, HBB, XDH |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.509E-14 | 1.093E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.699E-21 | 1.117E-18 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.410E-13 | 2.362E-11 | CAMK2B; SRC; MMP2; PTPN11; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; PTPN6; TP53; MET; TLR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.516E-09 | 8.755E-08 | APAF1; SRC; AKT1; PTK2B; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.174E-10 | 3.381E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.873E-09 | 8.755E-08 | HPGD; KMT2A; FLT3; MMP3; ATM; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.870E-08 | 8.385E-07 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; MAPK1; MET; TP53; PPARD |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.680E-09 | 8.755E-08 | CYP2C9; CYP2C8; CYP2A6; CYP2A13; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.361E-08 | 3.810E-07 | CYP2C9; CYP2C8; CYP2A6; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.141E-08 | 5.246E-07 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.278E-08 | 8.385E-07 | CYP2C9; CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.556E-08 | 1.346E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.369E-07 | 2.236E-06 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.979E-07 | 3.244E-06 | GSK3B; PIK3R1; BRCA1; PTK2; NFKB1; IGF1R; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.238E-07 | 2.887E-06 | ADORA2A; CNR2; CNR1; ADORA3; ADORA1; NMUR2; OPRK1; TRPV1; ADRA2C; ADRA2A; DRD4; TSHR |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.934E-07 | 3.244E-06 | CASP7; APAF1; LMNA; AKT1; MAPK1; ATM; PIK3R1; TP53; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.907E-07 | 2.875E-06 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.794E-07 | 8.876E-06 | PLA2G1B; MAOA; GAA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; CYP2C9; CYP2C8; CYP2A6; FUT7; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPL; XDH; CES1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.357E-07 | 2.887E-06 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.165E-07 | 8.876E-06 | GSK3B; HDAC3; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.286E-07 | 2.887E-06 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.042E-06 | 8.876E-06 | CAMK2B; GSK3B; AKT1; MAPK1; PTPN11; PIK3R1; TP53; NFKB1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 7.706E-07 | 7.950E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.662E-06 | 1.303E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.042E-06 | 8.876E-06 | ABCC1; ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.425E-06 | 1.164E-05 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.300E-06 | 2.156E-05 | GSK3B; CXCR1; SRC; AKT1; PTK2B; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 2.679E-06 | 1.810E-05 | GSK3B; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1; TLR2 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.482E-06 | 3.070E-05 | CAMK2B; ADORA2A; ADORA1; AKT1; MAPK1; PIK3R1; PPARA; NFKB1; TSHR |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.542E-06 | 1.780E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 6.189E-06 | 3.297E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.704E-06 | 2.342E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.439E-06 | 2.636E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 6.467E-06 | 3.336E-05 | GSK3B; AKT1; PTPN11; PIK3R1; PYGL; PPARA; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.870E-06 | 3.366E-05 | CASP7; MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 8.800E-06 | 3.920E-05 | ADORA2A; SRC; CNR1; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.883E-06 | 1.419E-05 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.053E-06 | 2.482E-05 | AKT1; MAPK1; PTPN11; PIK3R1; MET; HIF1A |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.579E-05 | 6.727E-05 | PLA2G1B; KDR; AKT1; MAPK1; PTPN11; PIK3R1; MET; NFKB1; IGF1R |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.224E-06 | 3.297E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.754E-06 | 3.366E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.173E-05 | 8.693E-05 | ABCC1; PIM1; CYP1B1; MAPK1; ATM; BRCA1; TP53; MMP9; MET; NFKB1 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.321E-06 | 3.416E-05 | AKT1; MAPK1; PTPN11; PIK3R1; TP53; NFKB1 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 5.264E-06 | 3.035E-05 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.321E-06 | 3.416E-05 | GSK3B; AKT1; MAPK1; PTPN6; PIK3R1; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.378E-05 | 9.323E-05 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.925E-06 | 3.613E-05 | CSNK2A1; SRC; MAPK1; PTPN6; MET; IGF1R |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.310E-05 | 1.794E-04 | POLB; HDAC3; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.889E-05 | 7.879E-05 | APAF1; AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 4.710E-05 | 1.649E-04 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 3.974E-05 | 1.442E-04 | CAMK2B; TRPA1; SRC; ALOX12; TRPV1; PIK3R1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.208E-05 | 1.500E-04 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.011E-04 | 3.197E-04 | ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 5.552E-05 | 1.844E-04 | GSK3B; AKT1; MAPK1; PTPN6; PIK3R1; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.050E-04 | 3.266E-04 | BACE1; GSK3B; CASP7; APAF1; MAPK1; MAPT; HSD17B10 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.595E-04 | 7.480E-04 | POLB; GSK3B; TERT; AKT1; ATM; PIK3R1; TP53; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.258E-04 | 9.123E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.503E-04 | 4.398E-04 | CAMK2B; APAF1; SRC; AKT1; MAPK1; NFKB1; TLR2 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.121E-04 | 3.380E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.121E-04 | 3.380E-04 | MMP2; PTK2B; PTPN11; PIK3R1; MMP9; PTK2 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.312E-04 | 9.142E-04 | CXCR1; AKT1; PTK2B; MAPK1; PTPN11; PIK3R1 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 4.267E-04 | 1.130E-03 | GSK3B; CASP7; AKT1; PIK3R1; PPARA; NFKB1 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.425E-04 | 1.418E-03 | PIM1; AKT1; PTPN6; STAT6; PTPN11; PIK3R1 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.027E-05 | 8.278E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.973E-04 | 8.445E-04 | CAMK2B; SRC; MMP2; PTK2B; MAPK1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 9.258E-04 | 2.268E-03 | GSK3B; CASP1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 4.190E-04 | 1.125E-03 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.919E-05 | 1.080E-04 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.919E-05 | 1.080E-04 | FABP4; ADORA1; AKT1; PIK3R1; TSHR |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.456E-04 | 9.408E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.233E-03 | 2.890E-03 | CSNK2A1; CDK1; PTPN11; TP53; NFKB1; TLR2 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 7.402E-04 | 1.836E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 6.003E-04 | 1.508E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 5.503E-04 | 1.419E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.490E-05 | 2.120E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.672E-05 | 1.027E-04 | CASP7; APAF1; CASP1; NFKB1; TLR2 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.796E-05 | 1.649E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.451E-03 | 3.307E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.660E-03 | 3.698E-03 | AKT1; MAPK1; ATM; PIK3R1; IGF1R |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.773E-03 | 3.904E-03 | PTK2B; MAPK1; PTPN6; PTPN11; PIK3R1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 7.493E-05 | 2.408E-04 | CXCR1; SRC; PTPN11; MET; NFKB1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.212E-03 | 4.712E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.015E-03 | 4.388E-03 | GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.212E-03 | 4.712E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 7.866E-03 | 1.542E-02 | SRC; AKT1; MAPK1; PIK3R1 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.564E-02 | 4.215E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.418E-02 | 4.017E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 8.091E-03 | 1.555E-02 | CAMK2B; CDK1; MAPK1; IGF1R |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.515E-02 | 2.651E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.880E-02 | 3.228E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 2.811E-02 | 4.514E-02 | HDAC3; ADORA2A; MAOA; MAPK1 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.320E-03 | 1.564E-02 | GSK3B; CDK1; ATM; TP53 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 4.051E-03 | 8.185E-03 | CAMK2B; AKT1; PYGL; PPARA |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.103E-05 | 4.803E-05 | CYP2A6; CYP3A4; XDH; CES2; CES1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.031E-02 | 1.853E-02 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 3.909E-03 | 8.066E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.051E-03 | 8.185E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 9.032E-03 | 1.670E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.641E-02 | 4.279E-02 | CAMK2B; GSK3B; MAPK1 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.189E-02 | 3.667E-02 | AKT1; MAPK1; PIK3R1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.189E-02 | 3.667E-02 | CSNK2A1; ATM; NFKB1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.584E-03 | 3.568E-03 | SRC; PIK3R1; MET; PTK2 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.239E-03 | 2.890E-03 | MAPK1; PTPN6; NFKB1; TLR2 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 2.267E-03 | 4.778E-03 | CASP1; MAPK1; PKN1; NFKB1 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.059E-03 | 2.531E-03 | AKT1; PTPN11; PPARA; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.894E-02 | 3.228E-02 | SRC; CDK1; MAPK1 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.370E-03 | 3.158E-03 | CASP7; CASP1; MAPK1; NFKB1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.916E-04 | 1.506E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.003E-03 | 2.428E-03 | APAF1; CDK1; ATM; TP53 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 9.482E-03 | 1.721E-02 | AKT1; MAPK1; PIK3R1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 8.029E-03 | 1.555E-02 | AKT1; PIK3R1; IGF1R |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.066E-02 | 1.900E-02 | CA2; CYP3A4; ABCG2 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 8.379E-03 | 1.564E-02 | SRC; MAPK1; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 8.379E-03 | 1.564E-02 | STAT6; NFKB1; TLR2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 5.824E-03 | 1.153E-02 | CASP1; MAPK1; NFKB1 |
hsa05144 | Malaria_Homo sapiens_hsa05144 | 3.806E-03 | 7.936E-03 | HBB; MET; TLR2 |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 4.262E-03 | 8.524E-03 | APAF1; CASP1; TP53 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.581E-02 | 4.215E-02 | MAPK1; PIK3R1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.224E-04 | 3.634E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.832E-02 | 4.514E-02 | FABP2; PLA2G1B |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.474E-02 | 2.603E-02 | MAPK1; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.573E-02 | 2.728E-02 | GAA; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 9.417E-03 | 1.721E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.537E-06 | 1.780E-05 | CYP2A6; CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; OPRK1; ADRA2C |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; CES1; PPARD |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; ADRA2C; CNR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; CNR2; PTK2B |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; CNR1; KDR; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; CNR1; PPARD |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; ADORA1 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | CES1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; SRC; IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; TERT; FLT3; MMP2; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; OPRK1; ADK; ACHE; TRPV1; TRPV1; IGF1R; ADORA2A; CDK1; ADRA2C; ADRA2A; TRPA1; CNR1; CNR2 |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | CES1 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; TLR2; CSNK2A1; CA1; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; TP53; KDR |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRK1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1; ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
NA: NA | Esophagus sensitivity | NA | TRPV1 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1; ADK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
C00-D49: Neoplasms | Breast cancer | C50 | TERT; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; KDR; KDR; KDR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADORA2A; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; CNR1; PPARD |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; CNR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
NA: NA | Edema | NA | CA2 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; TRPV1; ADORA2A; ADORA1; ADRA2C |
K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; ADORA1; CNR1; CNR1; CNR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT; FLT3 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; ADORA1 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; ADORA2A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRK1 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | OPRK1 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | OPRK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | CNR1; CNR1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; CES1; PPARD |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; CASP1; MMP3; CNR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; CNR1 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A; CES1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1; DRD4 |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; KDR; KDR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; CNR2 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; TLR2; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH; ADRA2C |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; CNR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3; CNR1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; CES1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1; DRD4 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; TRPV1; ADORA2A; ADORA1; CNR1; CNR2 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | KDR |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADORA3; ADORA2A; ADORA1; ADRA2C |
NA: NA | GIST | NA | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | OPRK1; CNR2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | OPRK1; ADRA2C; CNR1; CNR1; CNR1; CNR1; CNR1; CNR1; PPARD; PPARD |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; ATM; AXL; KDR |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; ADORA2A; ADORA1 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; OPRK1; ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; TRPV1; CNR2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |